Program
hydronidone
Also written as “Hydronidone capsules”, “Hydronidone” and “Hydronidone (270mg)”.
Its studies are mostly in Liver Cirrhosis · Hepatitis B, Chronic · Renal Insufficiency, Chronic · Hepatitis B, led by 2 companies.
Drug pageHydronidone: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GNI Groupits history only | 143 open or running | phase 3since Oct 9, 2021 | Oct 9, 2019 | Dec 1, 2026phase 1 · NCT07262333 |
| Shanghai Genomics | 10 open or running | phase 2since Jun 26, 2015 | Jun 26, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Shanghai Genomics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2015First study: phase 2 study in Hepatitis B, ChronicFirst studyNCT02499562 · 168 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Shanghai Genomics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02499562Hepatitis B, Chronic · China | 2 | Completed | Nov 20, 2020 | 168 |
How it is read
Names in the registry
- “Hydronidone capsules”, 7 entries
- “Hydronidone”, 4 entries
- “Hydronidone (270mg)”, 1 entry
- “[¹⁴C]Hydronidone”, 1 entry
- “Hydronidone Capsules”, 1 entry
Conditions, from the studies’ own filings
- Liver Cirrhosis, 6 studies
- Hepatitis B, Chronic, 5 studies
- Renal Insufficiency, Chronic, 1 study
- Hepatitis B, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.